Raffin et al. generated CAR-Tregs directed against citrullinated vimentin (CV), which is present abundantly in the extracellular matrix of inflamed joints in patients affected by Rheumatoid arthritis (RA) [138] and a phase I clinical trial is currently investigating the efficacy of autologous CAR-Tregs for treating RA. This evidence concerns the gene VIM and rheumatoid arthritis.